111 Inc begins selling Pfizer's COVID-19 treatment in China; shares up

111

13/12/2022 13:16

** U.S. shares of Chinese healthcare platform 111 Inc  YI.O 
up 7.6% at $3.81 premarket
    ** Almost 2.5 mln shares have traded hands, nearly 10x
stock's 25-DMA; among heaviest volumes across U.S. exchanges
    ** 111.com has started selling Pfizer's  PFE.N  oral
COVID-19 treatment Paxlovid in what appears to be the first
retail sale of the drug in China
    ** Paxlovid sold out just over half an hour after the
listing was reported in the media, according to YI's customer
service
    ** People can buy the medication if they submit a positive
COVID-19 test result
    ** It was not clear how many boxes were sold and when sales
would resume
    ** Stock has gained 1.1% YTD through last close
($1 = 6.9807 Chinese yuan renminbi)
 (Reporting by Ruhi Soni in Bengaluru)
 ((Ruhi.Soni@thomsonreuters.com
Twitter: https://twitter.com/ruhithere))